64 Management of EGFR tyrosine kinase inhibitor associated skin toxicity: a single centre experience

Lung Cancer ◽

10.1016/s0169-5002(16)30081-2 ◽

2016 ◽

Vol 91 ◽

pp. S23

Author(s):

L. Thomas ◽

M. Hadaki ◽

T. Sevitt ◽

R. Shah ◽

R. Burcombe ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Skin Toxicity ◽

Single Centre ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Single Centre Experience

Download Full-text

Dual-agent molecular targeting of growth factor receptors in hepatocellular cancer: Combining anti-EGFR antibody with an EGFR tyrosine kinase inhibitor

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-920152 ◽

2005 ◽

Vol 43 (05) ◽

Author(s):

A Hüther ◽

M Höpfner ◽

D Schuppan ◽

H Scherübl

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Hepatocellular Cancer ◽

Growth Factor Receptors ◽

Molecular Targeting ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Download Full-text

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Download Full-text

O-247 Molecular mechanisms of sensitivity and resistance to the HER1/EGFR-tyrosine kinase inhibitor erlotinib (Tarceva™)

Lung Cancer ◽

10.1016/s0169-5002(03)91905-2 ◽

2003 ◽

Vol 41 ◽

pp. S72 ◽

Author(s):

Roman Perez-Soler ◽

Qun Dai ◽

Yi-He Ling ◽

Marie Lee ◽

Glenn Kroog ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Molecular Mechanisms ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-11-0048 ◽

2011 ◽

Vol 10 (6) ◽

pp. 1102-1112 ◽

Author(s):

Monika E. Hegi ◽

Annie-Claire Diserens ◽

Pierre Bady ◽

Yuta Kamoshima ◽

Mathilde C. M. Kouwenhoven ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Pathway Analysis ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Preoperative Treatment ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Download Full-text

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Line Treatment ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan

Oncology Letters ◽

10.3892/ol.2019.10942 ◽

2019 ◽

Author(s):

Ching‑Hu Chung

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Clinical Outcomes ◽

Kinase Inhibitor ◽

Cancer Treatments ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

Oncogene ◽

10.1038/s41388-018-0517-4 ◽

2018 ◽

Vol 38 (9) ◽

pp. 1398-1409 ◽

Author(s):

Kimio Yonesaka ◽

Naoki Takegawa ◽

Satomi Watanabe ◽

Koji Haratani ◽

Hisato Kawakami ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Topoisomerase I ◽

Kinase Inhibitor ◽

Dna Topoisomerase I ◽

Antibody Drug Conjugate ◽

Egfr Tyrosine Kinase Inhibitor ◽

Dna Topoisomerase ◽

Egfr Tyrosine Kinase ◽

Download Full-text

Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer

Molecular Pharmaceutics ◽

10.1021/acs.molpharmaceut.8b00307 ◽

2018 ◽

Vol 15 (8) ◽

pp. 3216-3226 ◽

Author(s):

Chang Liu ◽

Tatiana Shaurova ◽

Suzanne Shoemaker ◽

Martin Petkovich ◽

Pamela A. Hershberger ◽

...

Keyword(s):

Lung Cancer ◽

Vitamin D ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Targeted Nanoparticles ◽

Egfr Tyrosine Kinase

Download Full-text

P3.CR-14 A Case of EGFR Tyrosine Kinase Inhibitor (TKI), Osimertinib Induced Pneumonitis in a Patient with Recurrent Fevers of Unknown Origin

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.08.1993 ◽

2018 ◽

Vol 13 (10) ◽

pp. S1033 ◽

Author(s):

D. Cuthbert ◽

Y. Chae

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Unknown Origin ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text